ARISTOCORT
LOE ApproachingNDAORALSYRUP
Approved
Sep 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an oral syrup small-molecule drug approved in 1959 as an NDA by Astellas. The generic name and mechanism of action are not currently disclosed in available data. This legacy product represents a mature therapeutic from the mid-20th century pharmaceutical era.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the brand team likely focuses on lifecycle extension and managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings suggest limited active hiring for ARISTOCORT-specific roles, reflecting the product's mature, declining commercial status. Career opportunities are concentrated in defending market share and managing the transition to generic competition rather than growth-oriented positions.
Brand ManagerProduct Manager
Worked on ARISTOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.